Meet Nanomerics at JPMorgan/Biotech Showcase

Nanomerics’ CSO, Professor Ijeoma Uchegbu will be at Biotech Showcase in January 2016 (11th - 13th January 2016). This meeting is colocated with the JP Morgan Healthcare Conference in San Francisco. Please contact us, if you would like to meet with Nanomerics in San Francisco.

Meet Nanomerics at APS PharSci 2015

Nanomerics CEO Prof A. Schatzlein will be presenting latest results of the development of MET nano-enabled therapies at the annual APS PharmSci Meeting.
The conference, the 6th of this series, will be held from the 6th 7th - 9th September 2015, at the East Midlands Conference Centre, Nottingham at Nottingham.
Prof Schatzlein will be presenting in the BSNM Nanomedicines and Biotherapeutics session.

Nanomerics Announces Completion of Major Preclinical Toxicology Programme on its Molecular Envelope Technology

Nanomerics today announced the successful completion of a major preclinical toxicology programme on its Molecular Envelope Technology (MET), paving the way for the technology’s clinical testing.  Safety pharmacology, mutagenicity and a range of 28 day repeat dose Good Laboratory Practice (GLP) standard toxicology tests have been completed on two species (rodent and non-rodent).

Meet us in Paris

 logo Nanomerics will be attending BioEurope Spring 2015 in Paris March 9th-11th.






Nanomerics' Oral Amphotericin B Promises Better Treatment for Millions has developed a nano-enabled orally active form of Amphotericin B which could provide improved access to efficacious therapy to millions of people affected by Leishmaniasis.

Nanomerics CEO Andreas Schatzlein presents at OBN Investor Forum

OBN logoAt the upcoming 4th OBN Investor & CEO networking forum Nanomerics CEO Prof A Schatzlein will be presenting an update on the development of Nanomerics' lead products NM0127, a nasal analgesic peptide to replace opioid pain therapies, and NM0131, a once daily non-oily nano-enabled form of cyclosporin A for the treatment of dry eye syndrome.  

Prof Martin Koltzenburg Joins Nanomerics Advisory Board

Nanomerics is pleased to announce the strengthening of its Scientific Advisory Board with the appointment of Professor Martin Koltzenburg.  Professor Koltzenburg’s appointment will  support the clinical development of iNanomerics' lead product NM0127, a novel pain therapeutic based on an endogenous peptide.

Fighting Fit - Nanomerics featured in CBI Business Voice Publication

moleculesIn the October edition of the CBI's  online publication 'Business Voice' journalist Dan Jellinek looks at how leading UK innovators contribute to the expanding UK life science sector. Nanomerics' CEO Prof Andreas Schatzlein describes how support from the EPSRC,  the Wellcome Trust, and Innovate UK has helped Nanomerics to translate scientific research into medicines which bring important patient benefits.

Antibodies to the Brain - A High Impact Collaboration

Nanomerics is embarking on a new EPSRC funded collaborative research project with the Danish pharmaceutical company H Lundbeck, UCL, and Exeter University.  

LogosAs part of the new collaboration, the company aims to develop new and exciting ways to deliver antibodies to the brain, building on the molecular envelope technology Nanomerics has developed to deliver previously undeliverable drugs to the organ.

UCL’s School of Life and Medical Sciences Celebrates Enterprise Successes

UCL Enterprise publicationSpin-out Nanomerics and its founders were highlighted in UCL’s School of Life and Medical Sciences recently launched  'Enterprise' publication. The brochure, available here, celebrates recent success stories of translation of scientific knowledge.